Skip to main content
Equibles
ADIA logo

ADIA · Adia Med, Inc.

Track ADIA — free

Use ADIA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADIA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.13 At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.”
View the 10-Q filed Aug 13, 2026
Market Cap
$11.33M
Shares
94.40M
Volume · Oct 19 2600 Avg daily vol (3M) 13.35K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.13 Open$0.13 Day$0.13–0.13 52W close$0.03–0.24 Avg vol 30d15K Short int460 · 0.0% float · 1.0d Short vol21% DataJan 2020–Oct 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.17M
Trailing 12 months
Net income (TTM)
−$277,355
Trailing 12 months
Revenue growth YoY
+310.8%
Year over year
Operating margin
-20.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$128,115
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+80.1%
Year over year · more shares
Price change (1Y)
+209.5%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $71,764 −$116,219 '25 Q1 · $118,146 −$123,997 '25 Q2 ▲145.6% $176,275 −$162,525 '26 Q1 LATEST ▲310.8% $485,385 $40,418 '26 Q2

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −1%
below
RSI (14) 49
neutral
MACD trend Positive
52-week position 48%
mid-range
Momentum
relative strength
Weak
1-month return 0%
trailing
6-month return −38%
trailing
YTD return +67%
this year
Relative strength −45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 29
low risk · 0–100
Fundamentals
Fair
Revenue growth +10880%
Y/Y
Gross margin 27%
contracting
Free cash flow $-192.4K
Quant / Vol
risk profile
Very High
Volatility 274%
annualized · 1-yr
Max drawdown −73%
past year
ATR 11.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−1% Neutral
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
48% Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 48% Range high $0
vs 200-day avg -4% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADIA
Adia Med, Inc.
this stock
$11.33M +66.7% +10879.7% — 0.0%
HCA
HCA Healthcare, Inc.
 $100.91B -0.2% +7.1% 15.3 2.2%
FSNUY
Fresenius SE & Co. KGaA
 $28.52B -11.7% — — 0.0%
THC
Tenet Healthcare Corp
 $21.45B +37.0% +0.9% 10.3 2.3%
EHC
Encompass Health Corp
 $12.01B +14.6% +10.5% 19.8 3.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
460
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
21%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
221
Value
$29
As of
Sep 21, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$700.5K
Net income (FY)
$-395.5K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 19, 2026
This year
9

Adia Med, Inc. sold CEO Larry Powalisz seven membership units (7%) in Adia Labs LLC for $350,000.00 cash, with use of proceeds requiring joint written approval from independent directors Monica Sher, M.D. and Richard Edwards, D.O.

View

Performance

5D 20D 120D MTD YTD
ADIA +28.7% +0.0% -37.5% +0.0% +66.7%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY +30.2% +0.9% -45.2% -0.5% +54.3%
Key facts CIK 1160420 CUSIP 00687W109 Visit website Investor relations